Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point‐of‐care p53 immunohistochemistry
Sign Up to like & getrecommendations! Published in 2025 at "Cancer"
DOI: 10.1002/cncr.35950
Abstract: The prolonged turnaround time for next‐generation sequencing (NGS) results may be a barrier to the timely selection of therapeutics in myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) with mutated TP53. Biomarker validation for early… read more here.
Keywords: early identification; identification tp53; acute myeloid; myelodysplastic neoplasms ... See more keywords
Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms
Sign Up to like & getrecommendations! Published in 2024 at "Annals of Hematology"
DOI: 10.1007/s00277-024-05664-5
Abstract: In low-risk Myelodysplastic Neoplasms (MDS), increased activity of apoptosis-promoting factors such as tumor necrosis factor (TNFα) and pro-apoptotic Fas ligand (CD95L) have been described as possible pathomechanisms leading to impaired erythropoiesis. Asunercept (APG101) is a… read more here.
Keywords: treatment; clone sizes; risk; myelodysplastic neoplasms ... See more keywords
Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS)
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Hematology"
DOI: 10.1007/s00277-025-06443-6
Abstract: MDS patients show a heterogenous prognosis which can be stratified by the IPSS-R in order to derive therapeutic implications. Based on 618 patients with myelodysplastic neoplasms belonging to the cytogenetic intermediate-risk group according to IPSS-R,… read more here.
Keywords: patients myelodysplastic; risk; group; intermediate risk ... See more keywords
MDS-PB13 Score - Blood based detection of aberrancies by flow cytometry in patients with suspected and confirmed Myelodysplastic Neoplasms
Sign Up to like & getrecommendations! Published in 2024 at "Leukemia"
DOI: 10.1038/s41375-024-02141-w
Abstract: TO THE EDITOR: Flow cytometry (FCM) of bone marrow (BM) samples is part of the integrated diagnostic approach for myelodysplastic neoplasms (MDS) [1 – 3]. Several FCM-based scoring systems e.g. the Ogata-score and integrated FCM-score… read more here.
Keywords: score; myelodysplastic neoplasms; flow cytometry; neoplasms mds ... See more keywords
Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms
Sign Up to like & getrecommendations! Published in 2024 at "Leukemia"
DOI: 10.1038/s41375-024-02234-6
Abstract: Myelodysplastic neoplasms (MDS) are characterized by clonal evolution starting from the compartment of hematopoietic stem and progenitors cells (HSPCs), leading in some cases to leukemic transformation. We hypothesized that deciphering the diversity of the HSPCs… read more here.
Keywords: hspcs; risk; lower risk; mds ... See more keywords
The prognostic role of lymphocyte to monocyte ratio (LMR) in patients with Myelodysplastic Neoplasms.
Sign Up to like & getrecommendations! Published in 2023 at "Hematology"
DOI: 10.1080/16078454.2023.2210929
Abstract: BACKGROUND Previous studies validated the prognostic significance of lymphocyte to monocyte ratio (LMR) in patients with solid tumors and some hematologic malignancies. However, the correlation between LMR and Myelodysplastic Neoplasms (MDS) was unclear. The study… read more here.
Keywords: ratio lmr; lymphocyte monocyte; lmr; lmr patients ... See more keywords
Computational Structural Genomics Meets Cryo-EM for the Analyses of Mitochondria-Encoded Enzyme Complexes: A Transformational Approach for Deep Variant Phenotyping in Myelodysplastic Neoplasms
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-193462
Abstract: Background : While the central role of genomic alterations in myelodysplastic neoplasms (MDS) is well recognized, most studies have focused on nuclear genome mutations, overlooking the potentially critical importance of the mitochondrial genome. Mitochondria are… read more here.
Keywords: variant; computational structural; analysis; structural genomics ... See more keywords
A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-Based Therapy - Interim Analysis Results of the Impress Study
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-194185
Abstract: Uwe Platzbecker, Steven Lane and Lionel Adès contributed equally. A study by the European Myelodysplastic Neoplasms Cooperative Group (EMSCO) Background: Hypomethylating agents (HMAs), alone or in combination with venetoclax, are the standard of care for… read more here.
Keywords: disease; treatment; safety; efficacy ... See more keywords
Safety and Efficacy of Luspatercept in Low-Risk Myelodysplastic Neoplasms with Anaemia
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-207749
Abstract: Background: Therapy of anaemia in people with low-risk Myelodysplastic Neoplasms (MDNs) is challenging. Luspatercept targets ineffective erythropoiesis. Objective: Define the safety and efficacy of luspatercept in people with low-risk MDNs and anaemia. Methods: A meta-analysis… read more here.
Keywords: low risk; risk; efficacy; myelodysplastic neoplasms ... See more keywords
Functional classification of monoallelic TP53 mutations refines prognostic stratification in myelodysplastic neoplasms
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-3835
Abstract: Introduction Myelodysplastic neoplasms (MDS) are a group of hematological disorders characterized by ineffective hematopoiesis. Mutations in the TP53 gene have emerged as one of the most significant negative prognostic factors. Despite the recognized negative impact… read more here.
Keywords: tp53 mutations; monoallelic tp53; myelodysplastic neoplasms; impact ... See more keywords
Clinical outcomes in spliceosome-mutant myelodysplastic neoplasms and Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-7038
Abstract: Spliceosomes facilitate the removal of non-coding introns from precursor messenger RNA via a macromolecular complex to form mature mRNA transcripts. Somatic mutations in genes encoding splicing factors are commonly seen in myeloid malignancies, especially in… read more here.
Keywords: treatment; type; leukemia; myelodysplastic neoplasms ... See more keywords